vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company developing cadisegliatin for type 1 diabetes treatment, has announced its participation in two major investor conferences in September 2025.
The company will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9, participating in one-on-one investor meetings. On the same day, management will also present at the Morgan Stanley 23rd Annual Global Healthcare Conference, featuring a fireside chat from 2:35 PM to 3:10 PM EST, along with individual investor meetings.
vTv Therapeutics (Nasdaq: VTVT), società biofarmaceutica in fase avanzata che sta sviluppando cadisegliatin per il trattamento del diabete di tipo 1, ha annunciato la partecipazione a due importanti conferenze per investitori nel settembre 2025.
L'azienda parteciperà al H.C. Wainwright 27th Annual Global Investment Conference il 9 settembre, con incontri individuali con investitori. Nello stesso giorno la direzione terrà anche una presentazione al Morgan Stanley 23rd Annual Global Healthcare Conference, con un fireside chat dalle 14:35 alle 15:10 EST e ulteriori meeting one-to-one.
vTv Therapeutics (Nasdaq: VTVT), una compañía biofarmacéutica en fase avanzada que desarrolla cadisegliatin para el tratamiento de la diabetes tipo 1, ha anunciado su participación en dos importantes conferencias de inversores en septiembre de 2025.
La empresa asistirá al H.C. Wainwright 27th Annual Global Investment Conference el 9 de septiembre, realizando reuniones individuales con inversores. Ese mismo día, la dirección también hará una presentación en el Morgan Stanley 23rd Annual Global Healthcare Conference, con un fireside chat de 2:35 PM a 3:10 PM EST y reuniones privadas con inversores.
vTv Therapeutics (Nasdaq: VTVT), 제1형 당뇨병 치료제 카디세글리틴(cadisegliatin)을 개발 중인 후기 임상 바이오제약사로, 2025년 9월 두 건의 주요 투자자 콘퍼런스에 참가한다고 발표했습니다.
회사는 9월 9일 H.C. Wainwright 27th Annual Global Investment Conference에 참석해 일대일 투자자 미팅을 진행합니다. 같은 날 경영진은 Morgan Stanley 23rd Annual Global Healthcare Conference에서 14:35~15:10(EST) 사이에 파이어사이드 채트 발표를 포함해 개별 투자자 미팅도 가질 예정입니다.
vTv Therapeutics (Nasdaq: VTVT), société biopharmaceutique en phase avancée développant le cadisegliatin pour le traitement du diabète de type 1, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025.
La société assistera au H.C. Wainwright 27th Annual Global Investment Conference le 9 septembre, où elle tiendra des réunions individuelles avec des investisseurs. Le même jour, la direction présentera également au Morgan Stanley 23rd Annual Global Healthcare Conference, avec un fireside chat de 14h35 à 15h10 (EST) et des rencontres individuelles avec des investisseurs.
vTv Therapeutics (Nasdaq: VTVT), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das Cadisegliatin zur Behandlung von Typ-1-Diabetes entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am 9. September an der H.C. Wainwright 27th Annual Global Investment Conference teilnehmen und Einzelgespräche mit Investoren führen. Am selben Tag wird das Management zudem auf der Morgan Stanley 23rd Annual Global Healthcare Conference präsentieren, darunter ein Fireside-Chat von 14:35 bis 15:10 EST sowie einzelne Investorengespräche.
- None.
- None.
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:
| H.C. Wainwright 27th Annual Global Investment Conference | |
| Date: | Tuesday, September 9, 2025 |
| Format: | 1x1 Investor Meetings Only |
| Morgan Stanley 23rd Annual Global Healthcare Conference | |
| Date: | Tuesday, September 9, 2025 |
| Format: | Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings |
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
When is vTv Therapeutics (VTVT) presenting at the Morgan Stanley Healthcare Conference 2025?
What conferences is vTv Therapeutics (VTVT) attending in September 2025?
What is vTv Therapeutics' (VTVT) main drug development focus?
What type of meetings will VTVT have at the H.C. Wainwright Conference?
